Rest Ez Inc. (RTEZ)

Executive Summary / Key Takeaways

• Zero Revenue, Maximum Valuation: Rest EZ reported no revenue for the nine months ended December 31, 2025, yet trades at a $1.93 billion enterprise value and $70 per share, representing one of the most extreme disconnects between fundamentals and market price in the micro-cap space.

• Going Concern Is Not Theoretical: Management explicitly states that "without additional capital, the Company may not be able to remain in business," with only $300 in cash and an accumulated deficit of $286,101 as of December 31, 2025, making insolvency a mathematical certainty without immediate funding.

• No Competitive Moat Exists: The company has "nothing proprietary about their product" and "no intellectual properties," operating in a sleep aid market dominated by Procter & Gamble (PG), Perrigo (PRGO), and Sanofi (SNY), whose combined resources and distribution make RTEZ's soft gel differentiation commercially irrelevant.

• Key Person Risk Is Absolute: With Dylan Carson as the sole executive officer and director, the entire corporate strategy, sales execution, and operational continuity rest on one individual, with no succession plan or independent oversight.

• Speculation, Not Investment: The current valuation can only be justified by speculative dynamics unrelated to business fundamentals, creating extreme downside risk of 100% capital loss against limited upside potential from an unlikely turnaround or acquisition.

Setting the Scene: A Company That Forgot How to Sell

Rest EZ, Inc., incorporated on October 17, 2016 as Amazing Ventures, Inc. and renamed in February 2018, operates a business model so simple it can be described in a single sentence: the company produces one sleep aid supplement, manufactured by an unaffiliated third party, and attempts to sell it online and through wholesale channels. This simplicity would be a strength if it generated profits, but the financial record reveals a business that peaked early and has since collapsed into operational stasis.

The company's trajectory tells a story of failed product-market fit. After reaching $519,443 in revenue for the fiscal year ending March 31, 2022—a figure that suggested modest traction in the $7-8 billion U.S. sleep supplements market—sales evaporated to just $5,000 in FY2024. By December 31, 2025, revenue had flatlined at zero for both the three and nine-month periods. This matters because it demonstrates that Rest EZ's initial sales were not repeatable or scalable, likely representing one-time channel fills or promotional bursts rather than sustainable consumer demand. The company has effectively spent three years proving that its product cannot compete in a market growing at 7-8% annually, where competitors like Procter & Gamble's ZzzQuil and Sanofi's Unisom command established shelf space and consumer loyalty.

The company's position in the value chain compounds this weakness. Manufacturing is outsourced to Sport Energy, a contract producer that makes liquid gels for other companies, meaning RTEZ has no production cost advantage, quality control differentiation, or manufacturing IP. Distribution relies on a website and direct sales by the CEO to wholesalers—a strategy that has yielded zero revenue for over a year. This matters because it shows RTEZ lacks the basic commercial infrastructure required to compete. While Perrigo leverages retailer partnerships to achieve 15.6% operating margins and Procter & Gamble spends billions on marketing to maintain 26.3% margins, Rest EZ cannot even generate a single dollar of top-line sales, indicating its go-to-market strategy has completely broken down.

Technology, Products, and Strategic Differentiation: The Illusion of Advantage

Rest EZ's product is a liquid gel capsule containing a standard blend of sleep aid ingredients: soybean oil, valerian root, melatonin, L-Theanine, and other common compounds. Management believes the soft gel form provides superiority "avoiding substantial product break down before digestion," but this claimed advantage is both unproven and indefensible. The company explicitly acknowledges it has "nothing proprietary about their product" and "no intellectual properties in connection with the capsules." This admission matters because it means any competitor can replicate the formulation, and many already offer soft gel variants. Without patents, clinical studies, or FDA approval—which management dismisses as a "lengthy and costly process"—the product is a commodity indistinguishable from private label alternatives sold at 20-50% discounts by Perrigo.

The lack of differentiation directly impacts pricing power and margins. In the sleep aid market, brand recognition and clinical validation drive premium pricing. Procter & Gamble's ZzzQuil commands shelf space through decades of consumer trust and national advertising. Sanofi's Unisom benefits from pharmaceutical heritage and regulatory expertise. Rest EZ offers none of these value drivers, forcing it to compete solely on price in a category where it cannot achieve scale. This explains why the company has sold only 33,235 bottles total in its history for $284,443—an average selling price of roughly $8.55 per bottle that likely barely covers variable costs, if at all. With zero revenue in the latest period, the product's economic value has effectively reached nil.

The company's R&D investment is non-existent. There are no disclosed plans for new formulations, extended-release versions, or combination products that could create a moat. While competitors invest billions in innovation—PG developing melatonin-gummies extensions, SNY exploring evidence-based OTC combinations—Rest EZ's static product line ensures it will continue losing share to both branded innovators and low-cost generics. This matters because it eliminates any plausible path to margin expansion or market share recovery. The product is a dead end, and management has no roadmap to change that reality.

Financial Performance & Segment Dynamics: The Mathematics of Insolvency

The financial statements read like a case study in corporate failure. For the nine months ended December 31, 2025, Rest EZ reported zero revenue, zero gross profit, and a net loss of $7,900. General and administrative expenses were $7,900—effectively the entire loss—representing the bare minimum to maintain corporate existence. This matters because it shows the company has already cut operations to the bone, yet still cannot achieve cash flow breakeven. There is no fat to trim; the business model itself is the problem.

The balance sheet reveals a company that has already ceased operations in all but name. Cash stands at $300, unchanged from March 31, 2025, indicating no operating activity. The accumulated deficit of $286,101 exceeds any plausible valuation of the company's assets, which consist of no inventory, no property, and no intangible assets beyond a website and some point-of-sale materials. This matters because it means shareholders' equity is mathematically negative, and the company exists solely through the forbearance of creditors and the CEO's provision of free office space. The $13,500 loan forgiveness by former president Brandon Sosa, satisfied through shares, represents the only "capital" injection in recent history—a trivial amount that underscores the complete absence of external investor interest.

The working capital position is a mirage. While the company technically has a $300 working capital surplus, this is meaningless when current liabilities include ongoing operational expenses and the looming requirement to either raise capital or liquidate. Management's own assessment states that "without additional capital, the Company may not be able to remain in business," which is not a risk factor but a statement of immediate reality. This matters because it frames the investment decision not as a question of valuation but of binary survival. Any analysis of margins, growth rates, or competitive positioning is academic until the company solves its existential funding crisis.

The comparison to competitors highlights the absurdity of RTEZ's market valuation. Procter & Gamble generates $84.3 billion in revenue with 51.19% gross margins and 26.30% operating margins. Perrigo delivers $1.11 billion quarterly revenue with 35.14% gross margins. Sanofi achieves 72.34% gross margins on €43.6 billion in sales. Rest EZ has zero revenue and zero margins. Yet RTEZ trades at a $1.93 billion enterprise value—higher than Perrigo's $1.37 billion market cap. This disconnect can only be explained by factors unrelated to business fundamentals: a microscopic float , potential ticker symbol confusion, or pure speculative momentum divorced from reality.

Outlook, Management Guidance, and Execution Risk: Vague Promises, Zero Credibility

Management's forward-looking statements lack specificity and credibility. The company plans "to build out its reputation further, and expand to additional wholesalers, retail chain stores, as well as expand sales to the public" over the next twelve months. This matters because it offers no concrete strategy, budget, or operational plan to achieve what the company has failed to do for three years. "Building reputation" is not a strategy; it's a hope. Without marketing resources—PG spends billions, RTEZ spends nothing—this plan is fantasy.

The execution risk is absolute. Mr. Carson is the sole executive officer and director, meaning every function from sales to accounting to compliance depends on one person. The company acknowledges "there can be no assurance that a suitable replacement could be found" upon his departure. This matters because it concentrates all operational risk in a single point of failure. If Carson resigns or becomes incapacitated, the company ceases to function instantly. This is not key person risk in the traditional sense; it's a single-person corporate entity masquerading as a public company.

Management's guidance is further undermined by material weaknesses in internal controls. The company lacks "sufficient internal accounting resources," "segregation of duties," an "independent board of directors or audit committee," and "written documentation of internal control policies." This matters because it means investors cannot trust the financial statements, however dire they appear. When a company cannot produce reliable financial reports, any assessment of its condition is provisional at best. The $286,101 accumulated deficit could be worse; the $300 cash balance could be overstated. This uncertainty layers additional risk onto an already uninvestable situation.

Risks and Asymmetries: The Certainty of Downside

The risks facing Rest EZ are not probabilities but certainties. The going concern risk is immediate and existential. Without capital, the company will cease operations—this is not a scenario but a countdown. The key person risk is absolute; the company's existence is coterminous with Mr. Carson's tenure. The competitive risk is total; RTEZ cannot compete with PG's branding, PRGO's cost structure, or SNY's regulatory expertise. The regulatory risk is asymmetric; while FDA approval isn't required for supplements, any change in dietary supplement oversight could impose costs that RTEZ cannot afford.

The only potential upside scenario is acquisition, but this is remote. A buyer would gain no proprietary technology, no meaningful revenue, no distribution network, and no brand value. The only conceivable asset is the ticker symbol itself, which might have speculative appeal. This matters because it defines the investment asymmetry: downside is 100% loss, upside is limited to a speculative premium disconnected from business value. This is not a risk/reward profile; it's a lottery ticket.

The company's beta of 1.72 suggests higher volatility than the market, but this is misleading for a stock that should be delisted. The zero book value and negative operational cash flow of -$44,705 mean traditional valuation metrics are meaningless. This matters because it forces investors to confront the reality that they are not buying a business but trading a piece of paper whose price is determined by supply and demand in the micro-cap speculative ecosystem, not corporate value creation.

Valuation Context: The $70 Question

At $70 per share, Rest EZ trades at an enterprise value of $1.93 billion. For a company with zero revenue, this multiple is infinite and therefore meaningless. The appropriate valuation metrics for this stage are not P/E or EV/EBITDA but cash runway and liquidation value. With $300 in cash and quarterly burn of approximately $2,633 (extrapolating from nine-month G&A of $7,900), the company has roughly 0.11 quarters of runway—about ten days. This matters because it quantifies the immediacy of the funding crisis. The stock should be valued on a probability-weighted basis: high probability of zero value in liquidation versus low probability of speculative premium.

Comparing RTEZ to peers is instructive only in highlighting the valuation absurdity. Perrigo trades at 0.32x sales because it generates $4.4 billion in annual revenue. Procter & Gamble trades at 4.02x sales on $84.3 billion in revenue. Rest EZ trades at infinite multiples on zero sales. The $1.93 billion enterprise value exceeds the market cap of many profitable small-cap companies with actual cash flows. This suggests the price reflects either a data error, extreme illiquidity, or a "story stock" premium that will collapse when reality reasserts itself.

For investors, the only relevant valuation exercise is assessing the post-dilution impact of any capital raise. If the company needs $500,000 to fund one year of operations—a conservative estimate given its burn rate—and raises it at a 50% discount to market, the share count would increase by over 14,000% at current prices, rendering existing holdings virtually worthless. This matters because it frames the investment decision: buying at $70 is betting on a miracle, not analyzing a business.

Conclusion: The Inescapable Arithmetic of Failure

Rest EZ, Inc. is not a turnaround story; it is a corporate corpse that has not yet been buried. The complete absence of revenue, the explicit going concern warning, the lack of proprietary assets, and the absolute dependence on a single executive create a risk profile that is binary and catastrophic. The $1.93 billion valuation and $70 stock price represent a market anomaly that cannot persist once operational reality is recognized.

The central thesis is not whether RTEZ will recover, but how quickly it will collapse. For fundamental investors, the stock is uninvestable at any price above zero. The only potential upside is a speculative premium driven by ticker symbol recognition or mistaken identity, while the downside is certain and total. The key variables to monitor are not revenue growth or margin expansion but the timing of the next capital raise and the terms of that financing, which will determine the dilution magnitude and likely delisting.

In a market filled with overvalued securities, RTEZ stands apart as a company whose valuation has become completely detached from any conceivable measure of business value. Investors treating this as a legitimate equity investment are not taking risk; they are making a donation to a failed enterprise with a functioning ticker symbol. The arithmetic is simple: zero revenue plus $286,101 in accumulated deficits equals a company that has already failed. The $70 price merely reflects a market inefficiency that will correct when the last speculative buyer realizes there is no business to own.